Topic

Reference

1 independent report

Independent ResearchReferenceBiotech China BD2026-07-27

China biotech licensing deals 2026: the running list

A running repository of cross border licensing transactions, upfront commitments, and milestone structures from Chinese drug developers.

Covered names from the Octans screener — Lowest P/E view.
Ticker	P/E	Cap $B	1D
JD	9.4	52.1	▲ +2.52%
PDD	11.2	179	▲ +2.65%
BABA	14.8	205	▲ +2.55%
TSM	18.9	612	▼ -1.07%
TCEHY	19.6	468	▲ +0.40%

Trailing (~5yr) P/E is indicative, not live

Octans Research’ independent Reference research as a structured, independent-only feed for platforms and distribution.